Compare UNH & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNH | MRK |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.9B | 260.2B |
| IPO Year | 1984 | N/A |
| Metric | UNH | MRK |
|---|---|---|
| Price | $331.86 | $106.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 15 |
| Target Price | ★ $407.88 | $111.93 |
| AVG Volume (30 Days) | 6.1M | ★ 14.5M |
| Earning Date | 01-27-2026 | 02-03-2026 |
| Dividend Yield | 2.66% | ★ 3.18% |
| EPS Growth | 24.92 | ★ 58.08 |
| EPS | ★ 19.22 | 7.56 |
| Revenue | ★ $435,159,000,000.00 | $64,235,000,000.00 |
| Revenue This Year | $12.94 | $1.98 |
| Revenue Next Year | $1.55 | $4.94 |
| P/E Ratio | $17.27 | ★ $14.13 |
| Revenue Growth | ★ 10.47 | 1.68 |
| 52 Week Low | $234.60 | $73.31 |
| 52 Week High | $606.36 | $107.05 |
| Indicator | UNH | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 70.67 |
| Support Level | $321.65 | $96.79 |
| Resistance Level | $334.60 | $100.94 |
| Average True Range (ATR) | 6.90 | 2.34 |
| MACD | -0.08 | 0.33 |
| Stochastic Oscillator | 44.48 | 96.13 |
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).